In renal cell carcinomas (RCC), NF-jB blockade is required for maximal bortezomib-induced apoptosis, and expression of the von Hippel-Lindau (VHL) tumor suppressor protein downregulates NF-jB. Thus, we hypothesized that expression of wild-type (wt) VHL sensitizes RCC cells to bortezomib by reducing constitutive NF-jB activity. Using isogenic paired cell lines with and without expression of wtVHL, we have confirmed that VHL expression reduces constitutive NF-jB activity. Moreover, VHL expression confers markedly heightened sensitivity to the growth inhibitory effects of bortezomib in vitro. The bortezomib IC 50 values were greater than two logs lower in the VHL-expressing cell lines compared to the VHL-deficient counterparts. By manipulating the level of constitutive NF-jB activity in an isogenic pair of RCC cell lines independently of VHL expression, we were able to demonstrate that the VHL sensitization effect is due to downregulation of NF-jB activity. These findings offer the enticing possibility of using VHL status as a molecular marker to identify RCC patients who may be sensitive to bortezomib. In particular, RCC patients who have nonclear-cell histologies as well as approximately 25% of clear-cell RCCs manifest expression of wtVHL and represent a subpopulation of patients that is apt to respond to bortezomib.
Introduction
An estimated 31 900 new cases of and 11 900 deaths from renal cell carcinoma (RCC) were anticipated for the year 2003 (Jemal et al., 2002) . RCC is quite resistant to chemotherapy, and immunotherapeutic agents, including interleukin-2 and interferon-alpha, are only modestly effective, with response rates of 10-20% (Glaspy, 2002; Godley and Kim, 2002; Nathan and Eisen, 2002) . The median survival of metastatic RCC remains at only 8 months. Clearly, novel and more effective treatments are required to alter the natural history of advanced RCC.
The 26S proteasome, the principal executioner of cytosolic protein degradation, has received much attention as a potential therapeutic target. The proteasome inhibitor, bortezomib (Velcadet, formerly PS-341), induces cytotoxicity in many tumor models, including prostate, colon, and pancreatic cancer, as well as multiple myeloma (Adams et al., 1999; Frankel et al., 2000; Cusack Jr et al., 2001; Hideshima et al., 2001) . The NF-kB pathway, which has well-known effects on regulating transcription of genes that inhibit apoptosis and stimulate proliferation and angiogenesis , is considered a critical target for bortezomibmediated growth inhibitory effects (Mitchell, 2003) . In fact, we have formally demonstrated that NF-kB inhibition is a crucial mediator of bortezomib-induced apoptosis in RCC cells . In a recent seminal study, expression of the von Hippel-Lindau (VHL) tumor suppressor protein, a ubiquitin ligase that targets various proteins for degradation by the ubiquitin-proteasome pathway, was shown to downregulate basal NF-kB activity in RCC cells (Qi and Ohh, 2003) . Thus, we postulated that VHL expression in RCC cells sensitizes to bortezomib by reducing basal NF-kB activity.
To prove this hypothesis, we evaluated the effects of bortezomib on isogenic pairs of RCC cell lines with and without wild-type (wt) VHL expression. To determine the contribution of differences in NF-kB activation status to VHL-mediated bortezomib sensitivity, we studied bortezomib effects on an isogenic pair of RCC cell lines in which NF-kB activity was manipulated independently of VHL expression. As loss of VHL expression and/or activity resulting from gross genetic lesions, point mutations, and VHL promoter hypermethylation occurs in approximately 75% of sporadic cases of RCC (Pavlovich et al., 2003) , a potential biochemical association between expression of wtVHL and sensitivity to bortezomib would have potential clinical relevance to choosing the subpopulation of wtVHL-expressing RCC patients as appropriate candidates for bortezomib treatment.
Results

Validation of VHL/NF-kB relationship
A recent report demonstrated that wtVHL expression decreases NF-kB activity in RCC cells (Qi and Ohh, 2003) . This conclusion, however, was based on results generated from only one isogenic pair of RCC cell lines with and without wtVHL expression (VHL-positive and VHL-deficient, respectively) (Qi and Ohh, 2003) . Thus, prior to studying the effects of bortezomib in VHLpositive versus VHL-deficient RCC cells, we first sought to confirm that VHL expression results in decreased basal NF-kB activity.
Using three isogenic pairs of RCC cells (786-0, UOK121, and UMRC6), in which the parental cell line is VHL-deficient (i.e. transfected with a control [C] vector) and the other has stable expression of wtVHL, we demonstrated that stable ectopic wtVHL expression markedly reduces NF-kB activity (Figure 1 ). In all three isogenic pairs of RCC cells, the control cells lacked VHL expression, and the cells with stable transfection of wtVHL cDNA expressed VHL protein ( Figure 1a , top panels). Importantly, electrophoretic mobility shift assays (EMSAs) confirmed that the VHL-positive counterpart had significantly reduced basal NF-kB activity ( Figure 1a To validate these findings, we employed a converse approach to modulating VHL expression. Thus, we investigated whether reducing VHL expression in RCC cells that endogenously express wtVHL results in augmentation of NF-kB activity. Toward this end, we employed RNA interference to silence expression of VHL in RCC cell lines (ACHN and Caki-1) that manifest endogenous expression of wtVHL. As shown in Figure 1b 
VHL sensitizes to bortezomib-mediated growth inhibition
Next, we studied the in vitro growth inhibitory effects of bortezomib on the isogenic paired cell lines with and without expression of wtVHL. We exposed these cells to various concentrations of bortezomib for 48 h and assessed overall cell viability with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Figure 2 shows examples of the survival curves for two of the paired cell lines: one pair in which the parental cell line is VHL-deficient (786-0 cells) and one in which the parental cell line is VHL-positive (ACHN cells). Bortezomib was far more effective in reducing the cell viability of 786-0 wtVHL cells compared to the 786-0 C cells (Figure 2a ). For the ACHN cells, which endogenously express wtVHL, cells transfected with control siRNA and, therefore, retained wtVHL expression were considerably more sensitive to bortezomib than ACHN cells transfected with VHL-specific siRNA (Figure 2b ). Thus, VHL-positive RCC cell lines manifest strikingly greater sensitivity to bortezomib compared to the VHL-deficient counterparts.
To extend these findings, we performed similar studies to include all five pairs of cell lines depicted in Figure 1 and calculated the concentration of bortezomib that results in 50% inhibition of cell growth (i.e. IC 50 values). As listed in Table 1 , the bortezomib IC 50 values for all five paired cell lines evaluated in Figure 1 clearly confirm the finding that VHL expression conferred markedly heightened sensitivity to the growth inhibitory effects of bortezomib in vitro. Whether wtVHL was ectopically expressed in RCC cells that lack endogenous wtVHL in the absence of bortezomib; data not shown); the equal in vitro growth rate of these VHL-positive and VHLdeficient cell lines has been previously reported by others (Iliopoulos et al., 1995; Gnarra et al., 1996) . Similarly, in the absence of bortezomib, the growth curves of ACHN and Caki-1 cells transfected with control or VHLspecific siRNA were identical. Thus, the differential effects of bortezomib on VHL-positive versus VHLdeficient cells cannot be attributed to intrinsic variations in proliferation. Next, to determine if apoptosis contributes to the growth inhibitory effects of bortezomib, we employed the TUNEL (terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling) method to assay apoptosis of bortezomib-treated paired cell lines. As shown in Figure 3 , bortezomib induced apoptosis in a dose-dependent manner in 786-0 cells and was more potent in this regard in VHL-positive cells. Similar results were obtained for the UMRC6 and UOK121 paired cell lines (data not shown).
We also sought to characterize the specificity of the VHL sensitization effect. Thus, we considered that VHL expression might sensitize RCC cells to any cytotoxic stimulus. However, when we tested the cytotoxic effects of the chemotherapeutic agent, paclitaxel, across a wide range of concentrations on three of the isogenic pairs of RCC cells, the paclitaxel IC 50 values were similar in VHL-positive and VHL-deficient cells (Table 1) . Thus, VHL expression did not result in increased sensitivity to paclitaxel, indicating that VHL does not nonspecifically sensitize to all apoptotic stimuli.
VHL sensitization to bortezomib is mediated by NF-kB
Based on these findings, our recent report that the NFkB inhibitory effect of bortezomib is required for maximal apoptosis of RCC cells , and the well-described antiapoptotic effects of NF-kB (Baldwin Jr, 2001), we hypothesized that heightened bortezomib sensitivity of VHL-positive RCC cells is due to their lower levels of constitutive NF-kB activity. To formally prove this hypothesis, we engineered the 786-0 isogenic pair of RCC cell lines with and without ectopic expression of wtVHL to manifest similar degrees of NFkB activity. Our strategy to modulate NF-kB activity independently of VHL expression involved downregulating NF-kB activity in these cells by transduction of an adenoviral vector that expresses the IkB super repressor /well) in triplicate and exposed to bortezomib (0, 0.001, 0.01, 0.1, 1, 10 mM) for 48 h. RCV was determined from MTT values and was used to calculate IC 50 values. C siRNA ¼ control duplex siRNA transfection; wtVHL siRNA ¼ transfection with VHL-specific siRNA. For UMRC6 C, the IC 50 value was >10 mM (the highest concentration of bortezomib that was tested); the value within parentheses is the estimated IC 50 value based on extrapolation of the line of best fit. ND ¼ not done. Differences in bortezomib IC 50 values between each member of all isogenic pairs reached statistical significance at Po0.05 (two-tailed, equal variance P-values) VHL sensitizes to bortezomib J An et al (Ad-IkB-SR). The IkB-SR contains mutations at the phosphorylation sites (Ser 32 to Ala and Ser 36 to Ala), which prevent its phosphorylation, dissociation from NF-kB, and subsequent degradation by the ubiquitinproteasome pathway, and thereby blocks NF-kB activity. As shown in Figure 4a , the Ad-IkB-SR at a multiplicity of infection (MOI) of 5 completely inhibited basal NF-kB activity in both partners of the 786-0 isogenic pair of RCC cells (top panels), which rendered them approximately equally sensitive to bortezomib (bottom panel). Importantly, transduction of the AdIkB-SR had no effect on cell viability in the absence of bortezomib (Figure 4a , bottom panel, bortezomib concentration ¼ 0), indicating that NF-kB blockade is not sufficient to induce cytotoxicity in this cell model.
To confirm these findings, we also used RNA interference of the NF-kB family member, p65 (RelA), as an alternative approach to engineer the paired 786-0 RCC cell lines to display similar levels of NF-kB activity. Figure 4b demonstrates that p65 RNA interference specifically reduced p65 protein expression (top panels), inhibited constitutive NF-kB activity by EMSA (middle panel), and caused the VHL-positive and VHLdeficient 786-0 cells to exhibit approximately equal sensitivity to bortezomib (bottom panel). p65 RNA interference did not completely block NF-kB activity in the VHL-deficient 786-0 C cells (Figure 4b , middle panel), which manifest significantly higher basal NF-kB activity compared to the wtVHL-expressing counterpart. Consequently, the control 786-0 cells transfected with p65 siRNA were slightly more resistant to bortezomib, especially at lower drug concentrations (0.1 and 1 mM), than the 786-0 wtVHL cells, in which transfection with p65 siRNA completely blocked NF-kB activity (Figure 4b , middle panel). These latter results support the notion that there is a dose effect of NF-kB activation on sensitization to bortezomib. Similar to transduction with the Ad-IkB-SR, selective NF-kB inhibition by gene silencing of p65 alone did not affect cell viability (Figure 4b , bottom panel, bortezomib concentration ¼ 0).
Taken together, our adenoviral and RNA interference studies clearly demonstrate that when isogenic RCC cell lines, which differ in their VHL status, are engineered to manifest comparable degrees of basal NF-kB activity, they exhibit similar sensitivity to bortezomib. Thus, VHL markedly sensitizes RCC cells to bortezomib by downregulating basal NF-kB activity.
We considered the possibility that bortezomib completely blocks NF-kB activity at a low threshold concentration in VHL-positive and VHL-deficient cell lines, in which case one would predict that bortezomib, at a concentration at or above this threshold, would induce a similar degree of cytotoxicity in VHL-positive and VHL-deficient cells. To eliminate this possibility, we assessed the degree of NF-kB activation in isogenic paired RCC cell lines upon exposure to increasing concentrations of bortezomib. As shown in Figure 5 , bortezomib inhibited NF-kB in a dose-dependent manner. At all concentrations of bortezomib, the VHL-deficient counterpart had a higher degree of basal NF-kB activation than the VHL-positive cell line. These results effectively exclude the possibility of a bortezomib threshold effect on NF-kB and, therefore, further 
Discussion
Here, we report two critical findings with respect to the effects of proteasome inhibition on RCC cells. First, RCC cells that express wtVHL are more sensitive to the proteasome inhibitor, bortezomib, than VHL-deficient RCC cells. The difference in sensitivity between VHLpositive versus VHL-deficient cells is not trivial as evidenced by an approximately two log difference in the bortezomib IC 50 values observed in five isogenic pairs of RCC cells. Second, this differential sensitivity is predominantly attributable to VHL-mediated downregulation of NF-kB activity, as demonstrated by our studies in which we were able to alter sensitivity to bortezomib by modulating NF-kB activity independently of VHL expression by using either of two strategies (ectopic expression of the IkB-SR and p65 RNA interference). At higher concentrations of bortezomib (1-10 mM), modulation of NF-kB with the IkB super repressor was sufficient to render VHL-positive and VHL-deficient cell lines equally sensitive to bortezomib (Figure 4a) . However, at lower concentrations of bortezomib (0.1 mM), VHL-positive cells exhibited somewhat increased sensitivity to bortezomib compared to the VHL-deficient counterparts despite pretreatment with the IkB super repressor (Figure 4a) . Thus, at lower concentrations of bortezomib, NF-kB-independent effects may modulate the increased sensitivity to bortezomib in VHL-positive cells. One possible mechanism that may contribute to this phenomenon relates to heightened transforming growth factor-a (TGF-a) expression in VHL-deficient cells, which occurs through HIF2a-induced transcription of TGF-a (de Paulsen et al., 2001; Gunaratnam et al., 2003) . TGF-a activates the epidermal growth factor receptor, which in turn may engage several biochemical pathways (e.g. AKT, JAK/STAT) that inhibit apoptosis and render cells more resistant to apoptotic stimuli such as bortezomib (Jorissen et al., 2003) . These findings add to our previous report that maximal apoptosis of RCC cells by bortezomib is dependent on the NF-kB inhibitory effect of bortezomib and underscore the importance of NFkB in mediating bortezomib-induced cellular effects in RCC cells. Although NF-kB inhibition appears to be crucial in mediating bortezomib-induced cytotoxicity in RCC cells, NF-kB blockade alone did not affect cell viability. This is consistent with previous reports by us and others (Oya et al., 2001; An et al., 2004) . Thus, biochemical effects independent of NF-kB clearly play a role in mediating bortezomib-induced cytotoxicity. For example, activation of the c-Jun N-terminal kinase has been shown to be important for bortezomib-induced apoptosis of multiple myeloma cells .
The mechanism whereby VHL regulates NF-kB activity remains to be elucidated. It was postulated by Qi and Ohh (2003) that VHL may inhibit NF-kB by targeting atypical protein kinase C, an upstream activator of the NF-kB pathway, for ubiquitination and subsequent degradation. The precise mechanism of VHL-mediated NF-kB blockade is an area of active investigation by several groups.
Our finding that wtVHL expression sensitizes to bortezomib may have potential relevance to the clinical management of metastatic RCC, which remains an essentially incurable disease. Specifically, our results offer the enticing possibility of using VHL status as a molecular marker to identify RCC patients who may be sensitive to bortezomib. This may be particularly relevant for non-clear-cell histologies of RCC (e.g. papillary and chromophobe RCC), virtually all of which express wtVHL (Pavlovich et al., 2003) . In addition, immunotherapy is not typically offered to patients with non-clear-cell histologies because of its lack of effect in this patient subpopulation (Atkins et al., 2004) . In fact, no consistently active therapy for patients with metastatic non-clear-cell RCC exists. In addition, bortezomib may also represent an alternative treatment strategy in the approximately 25% of cases of clear-cell RCC that do manifest wtVHL expression (Pavlovich et al., 2003) . As a drug that has already received US Food and Drug Administration approval for relapsed/refractory multiple myeloma , bortezomib has a demonstrated safety and toxicity profile and, therefore, is a particularly attractive candidate for further clinical study in RCC patients.
It should be pointed out that a recent clinical trial of bortezomib in RCC patients showed a low response rate (Davis et al., 2004) . However, we believe that the lack of clinical efficacy in this trial was a reflection of the fact that most cases of RCC are VHL-deficient. In this clinical trial, the histopathologic subtypes of the RCC subjects were not reported. However, one would expect that most of the patients enrolled in this trial had clearcell RCC, because this histologic subtype comprises at least 75% of all RCC cases. As clear-cell RCC is overwhelmingly VHL-deficient (Pavlovich et al., 2003) , these patients would be anticipated to manifest high constitutive NF-kB activity. Thus, based on our in vitro data, it is not surprising that bortezomib resulted in low response rates in unselected RCC patients in this clinical trial.
Materials and methods
Cell lines and reagents
The ACHN and Caki-1 cell lines, which endogenously express wtVHL (wtVHL), were purchased from American Type Culture Collection (Manassas, VA, USA). In addition, we obtained three pairs of isogenic RCC cell lines; each pair consists of a parental cell line, which lacks endogenous expression of wtVHL (VHL-deficient) and has been transfected with an empty vector control (C) plasmid, and one cell line that stably expresses wtVHL (VHL-positive). These paired RCC cell lines, 786-0 C/786-0 wtVHL (from W Kaelin, Dana Farber Cancer Institute), UOK121 C/UOK121 wtVHL (from J Gnarra, Louisiana State University), and UMRC6 C/ UMRC6 wtVHL (from B Zbar, National Cancer Institute) have been described (Chen et al., 1995; Iliopoulos et al., 1995; Gnarra et al., 1996) . All cell lines were cultured in Dulbecco's modified Eagle's medium (Omega Scientific, Thousand Oaks, CA, USA) plus 10% fetal bovine serum (Hyclone, Logan, UT, USA) plus antibiotics (100 U/ml of penicillin and 100 mg/ml of streptomycin; Omega Scientific) in a humidified atmosphere containing 5% CO 2 in air.
Bortezomib was supplied by Millennium Pharmaceuticals, Incorporated (Cambridge, MA, USA), and was dissolved in dimethyl sulfoxide (DMSO). For all experiments, the final DMSO concentration was maintained at 0.1%.
Cell viability and apoptosis assays
Cell viability was measured by the MTT assay as described previously . Relative cell viability (RCV) was calculated by normalizing MTT data to that of the respective untreated samples. Apoptosis was measured by the TUNEL method using the In situ Death Detection Kit, TMR Red (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. After TUNEL staining, cells were analysed on a Becton Dickinson FACS Caliber flow cytometer with CellQuest software (BD Biosciences).
Electrophoretic mobility shift assay
Cells were washed with cold PBS, and Buffer A (10 mM of (pH 7.9) HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM DTT, 200 mM PMSF, 1 mM leupeptin, 1 mM aprotinin, and 100 mM EDTA) was then added prior to pulverization with a tissue grinder. Subsequently, nuclei were pelleted, lysed with Buffer C (20 mM (pH 7.9) HEPES, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 M EDTA, 25% glycerol, 1 mM DTT, and 200 mM PMSF), and then passed several times through a 25-gauge needle. Debris was removed by centrifugation.
Wt and mutant kB oligonucleotide probes were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Nuclear protein (15 mg) was combined with end-labeled, double-stranded oligonucleotide probe, 1 mg of poly-dIdC (Amersham Pharmacia Biotech, Piscataway, NJ, USA), 1 mg of BSA, and 5 mM spermidine in a final reaction volume of 20 ml for 20 min at room temperature. The DNA protein complex was run on a 4% nondenaturing polyacrylamide gel with 0.4 Â TBE running buffer prior to subsequent autoradiography. Cold-competition experiments were performed with a 100-fold molar excess of double-stranded, cold wt or cold mutant kB oligonucleotide probes.
Adenoviral vectors
An adenoviral vector that contains an IkB 'super repressor' (Ad-IkB-SR), which potently inhibits NF-kB activity, and the control vector (Ad-CMV), which were amplified, purified, and titered in 293 cells, were a gift from Raj Batra (UCLA). The IkB-SR contains mutations at the phosphorylation sites (Ser 32 to Ala and Ser 36 to Ala), which prevent its phosphorylation, dissociation from NF-kB, and subsequent degradation by the ubiquitin-proteasome pathway, and thereby blocks NF-kB activity.
RNA interference
Target sequences for siRNA sequences were as follows: TransIT-TKO transfection reagent (Mirus, Madison, WI, USA) was used to transfect siRNA dulplexes into 786-0 cells according to the manufacturer's instructions.
